Coronary artery disease in young adults: current trends and prospects in diagnosis and treatment

This article emphasizes the relevance of the problem of ischemic heart disease (IHD) among young people, highlighting the need to update and deepen knowledge about diagnostic and treatment methods. The article presents a review of contemporary research on the diagnosis and treatment of IHD in youth, paying special attention to the study of the effectiveness and safety of the latest diagnostic methods, the influence of genetic factors, as well as the significance of pharmacological and non-pharmacological approaches to treatment. Research results confirmed the high effectiveness of multi-slice computed tomography of the coronary arteries and cardiac MRI in diagnosing IHD, particularly for early detection of the disease. Significant genetic markers have been identified that can be used for early diagnosis of IHD, especially in patients with a family history of the disease. The necessity of integrating various diagnostic approaches, considering genetic factors, and focusing on lifestyle in the prevention and treatment strategies for IHD in young individuals is noted. The findings of this review may be useful for specialists in cardiology, public health, and medical education.

1. Kosolapov VP, Yarmonova MV. Analysis of high cardiovascular morbidity and mortality in the adult population as a medical and social problem and ways to solve it. Ural Medical Journal. 2021;20(1):58-64. (In Russian)].

2. Boytsov S.A., Nikulina N.N., Yakushin S.S. et al. Sudden cardiac death in patients with coronary heart disease: prevalence, detectability, and problems of statistical recording. Russian Journal of Cardiology. 2011;2:59–64. (In Russian)].

3. Usacheva E.V., Nelidova A.V., Kulikova O.M., Flianku I.P. Mortality of the working–age population in Russia from cardiovascular diseases. Hygiene and Sanitation. 2021;100(2):159–165. (In Russian)].

4. URL: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death

5. Our World in Data. Cardiovascular diseases number of deaths by age, World. [Ele ctronic resource]. URL: https://ourworldindata.org/grapher/cardiovascular-disease-deaths-by-age [access date 2023 Oct 13].

6. Kicherova O.A., Reichert L.I., Akhmetyanov M.A. Risk factors of ischemic stroke. The role of vitamin D. Ural Medical Journal. 2021;20(4):93–8. (In Russian)].

7. Gulya M.O., Mochula A.V., Maltseva A.N. et al. Combined myocardial perfusion scintigraphy and computed tomography: diagnostic and prognostic signifi cance in ischemic heart disease. Russian Cardiologic Journal. 2022;27(6):108–117. (In Russian)].

8. Novikova I.A., Khlynova O.V., Nekrutenko L.A. Profi le of myocardial infarction risk factors: focus on young age. Health Risk Analysis. 2021(3):160–6. (In Russian)].

9. Galyavich AS., Baleeva L.V., Galeeva Z.M. et al. Eff ective pharmacological correction of risk factors in a patient with coronary artery disease. A clinical case. Cardiovascular Therapy and Prevention. 2022;21(8):90–6. (In Russian)].

10. Kubareva M.I., Ibatov A.D. Psychosocial factors and ischemic heart disease. Therapeutic Archive. 2019;91(12):70–74. (In Russian)].

11. Kramm M.N., Kopylov F.Y., Chomakhidze P.Sh. et al. On improving the diagnostic accuracy of the stress electrocardiographic test in detecting signs of transient myocardial ischemia. Russian Journal of Cardiology. 2020;25:47. (In Russian)].

12. Atabaeva L.S., Saidova M.A., Shitov V.N. et al. Speckle tracking technology in combination with myocardial contrast stress echocardiography — an additional method of assessing myocardial ischemia. Cardiological Bulletin. 2021;16(2):43–52. (In Russian)].

13. Atabaeva L.S., Saidova M.A., Shitov V.N., Staroverov I.I. Possibilities of contrast stress echocardiography in detecting myocardial ischemia in patients with various coronary artery lesions. Therapeutic Archive. 2020;92(4):45–50. (In Russian)].

14. Polidanov M.A., Blokhin I.S., Pozdnyakov M.V. et al. Modern technologies of non– invasive ambulatory ECG monitoring: basic principles of application, directions of development and improvement. Innovative paradigm of natural sciences development. 2020:93–103. (In Russian)].

15. Voltov A.A., Moiseeva Ya.I. Coronary angiography as one of the main methods for diagnosing cardiovascular diseases. Achievements of modern science. 2020:52–56. (In Russian)].

16. Pashkevich A.V., Khvorova A.D. Evaluation of the rationale for scheduling coronary angiography in patients with coronary artery disease. Materials of the XX interregional scientifi c and practical conference of students and young scientists. 2021:12– 13. (In Russian)].

17. Mal G.S., Samko G.N. Contemporary views on the diagnosis and treatment of coronary artery disease. Bulletin of Science. 2024;1(1(70)):304–8. (In Russian)].

18. Brow n J.C., Gerhardt T.E., Kwon E. Risk Factors for Coronary Artery Disease. StatPearls Publishing. 2023.

19. Patrick M.T., Li Q., Wasikowski R. et al. Shared genetic risk factors and causal association between psoriasis and coronary artery disease. Nature communications. 2022;13(1):6565. DOI: 10.1038/s41467-022-34323-4

20. Kara tzia L., Aung N., Aksentijevic D. Artifi cial intelligence in cardiology: Hope for the future and power for the present. Frontiers in cardiovascular medicine. 2022;9:945726. DOI: 10.3389/fcvm.2022.945726

21. Sayadia S.B., Elloumi Y., Kachouri R. Automated method for realtime AMD screening of fundus images dedicated for mobile devices. Medical and biological engineering & computing. 2022;60(5):1449–1479. DOI: 10.1007/s11517-022-02546-8

22. Graby J., Khavandi A., Thompson D. CT coronary angiographyguided cardiovascular risk screening in asymptomatic patients: is it time? Clinical radiology. 2021;76(11):801–811. DOI: 10.1016/j.crad.2021.07.010

23. Xu M., Zheng J., Hou T. et al. SGLT2 inhibition, choline metabolites, and cardiometabolic diseases: a mediation mendelian randomization study. Diabetes care. 2022;45(11):2718–2728. DOI: 10.2337/dc22-0323

24. Nelson K., Fuster V., Ridker P.M. Low-dose colchicine for secondary prevention of coronary artery disease: JACC Review Topic of the Week. Journal of the American College of Cardiology. 2023;82(7):648–660. DOI: 10.1016/j.jacc.2023.05.055

25. Gaudel P., Neupane S., Koivisto A.M. et al. Eff ects of a lifestylerelated risk factor modifi cation intervention on lifestyle changes among patients with coronary artery disease in Nepal. Patient education and counseling. 2021;104(6):1406–1414. DOI: 10.1016/j.pec.2020.11.030

26. Shao C., Wang J., Tian J. et al. Coronary artery disease: from mechanism to clinical practice. Advances in experimental medicine and biology. 2020:1–36. DOI: 10.1007/978-981-15-2517-9_1

27. Wang K., Shi X., Zhu Z. et al. Mendelian randomization analysis of 37 clinical factors and coronary artery disease in East Asian and European populations. Genome medicine. 2022;14(1):63. DOI: 10.1186/s13073-022-01067-1

28. Kasimova N.K. Modern tactics of treatment of coronary artery disease. Life Sciences and Agriculture. 2022;3(11):67–73. (In Russian)].

29. Lipovetsky B. Dyslipidemias, atherosclerosis and their connection with coronary heart disease and cerebral disease. Litres, 2022. (In Russian)].

30. Nosov A.E., Baydina A.S., Ustinova O.Yu. Air pollutants as risk factors for developing cardiometabolic pathology: an analytical review. Risk Analysis and Health. 2021;(4):181–94. (In Russian)].

31. Elagizi A., Kachur S., Carbone S., et al. A review of obesity, physical activity, and cardiovascular disease. Current obesity reports. 2020;9(4):571–581. DOI: 10.1007/s13679-020-00403-z

32. Bahls M., Leitzmann M.F., Karch A. et al. Physical activity, sedentary behavior and risk of coronary artery disease, myocardial infarction and ischemic stroke: a two-sample Mendelian randomization study. Clinical research in cardiology: offi cial journal of the German Cardiac Society. 2021;110(10):1564–1573. DOI: 10.1007/s00392-021-01846-7

33. Dey S., Sun E., Frishman W.H. et al. Sleep disorders and coronary artery disease. Cardiology in review. 2023;31(4):219–224. DOI: 10.1097/CRD.0000000000000478

34. Churilin M.I., Kononov S.I., Luneva Yu.V. et al. Polymorphic variants of intracellular cholesterol transporters genes: association with blood lipid levels, intima-media thickness, and development of coronary artery disease. Genetics. 2020;56(2):225–233. (In Russian)].

35. Grundy S.M., Stone N.J., Bailey A.L. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/ PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019;73(24):285–350.

36. Knuuti J., Wijns W., Saraste A. et al. The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J. 2020;41:407–77. DOI: 10.1093/eurheartj/ehz425

37. Bershtein, L.L. New opportunities for reducing residual risk in coronary artery disease. Cardiology. 2020;60(11):110–116. (In Russian)].

38. Ridker P.M., Everett B.M., Thuren T. et al. (2017). Antiinfl ammatory Therapy with Canakinumab for Atherosclerotic Disease. The New England Journal of Medicine. 2017;377(12):1119–1131. DOI: 10.1056/NEJMoa1707914

39. Yavelov I.S. Prevention of cardiovascular events in patients with stable coronary artery disease: myocardial revascularization or drug therapy? Cardiovascular Therapy and Prevention. 2021;20(3):65– 72. (In Russian)].

40. Roitberg G.E., Slastnikova I.D. Modern approaches to optimal antithrombotic therapy in stable coronary artery disease. Archive of Internal Medicine. 2020:348–356. (In Russian)].

41. Eikelboom J.W., Connoly S.J., Bosch J. et al., for the COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N. Engl. J. Med. 2017;377:1319–30. DOI: 10.1056/NEJMoa1709118

42. Connolly S., Eikelboom J., Bosch J. et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. Published Online November 10, 2017. DOI: 10.1016/S0140-6736(17)32458-3

43. The importance of compass study results for clinical practice conclusion of the expert council on November 22, 2017. Atherothrombosis. 2018;(1):19–25. (In Russian)].

44. Rodionova L.V., Shvetsova E.N., Tsivanyuk M.M. et al. Features of diagnosis and course of coronary heart disease in young people: a clinical case. Pacifi c Medical Journal. 2021;4(86):95–97. (In Russian)].